SK Biopharmaceuticals, CO., Ltd, a leading biotech company pioneering in commercialisation, development and research of oncology and central nervous system (CNS) treatments, have declared its license partnership deal with the Wisconsin Alumni Research Foundation (WARF) to further obtain the exclusive global rights for manufacturing, commercialisation and research and development (R&D) of WARF’s ‘WT-7695’. The WT-7695 is a preclinical level radiopharmaceutical therapy candidate established in partnership with the University of Wisconsin-Madison.
This intelligent agreement symbolises SK Biopharmaceuticals’ leading second-in-licensed asset in the field of radiopharmaceutical therapy, after its first asset ‘SKL35501’, which led last year. After these favorable instances within the company, SK Biopharmaceuticals never stopped to further strengthen its build-up in the radiopharmaceutical field via a supply deal with a Belgian radioisotope producer, PanTera and a U.S.-based nuclear innovation company, TerraPower.
With these supply agreements, SK locked the Actinium-225 via various other research partnership agreements in a chain to enlarge its potential and expertise throughout the full-stack radiopharmaceutical value chain.
With this licence agreement, SK Biopharmaceuticals has continued its step to capture the well-balanced growth smart strategy that will power up the internal potential and extend the collaboration period to enhance R&D in radiopharmaceutical therapy. The company targets to build a strong radiopharmaceutical value chain, covering radioisotope sourcing, drug discovery and clinical and preclinical development.
The CEO of WARF, Erik Iverson, said, “This deal represents the commitment of CA9 as a focused one in modernising cancer treatment for the wide patient group. We’re highly proud and delighted by this partnership between the University of Wisconsin-Madison researchers and our WARF Therapeutics team. The progress of both companies has unlocked the pathway for this collaboration with SK Biopharmaceuticals. We both are dedicated towards elevating the development of this proven therapy and further introducing it closely to the patients in need.”
The CEO of SK Biopharmaceuticals, Donghoon Lee, also expressed his excitement and the chance to flaunt its R&D potential and branch out its radiopharmaceutical therapy portfolio.
The WT-7695 is a compact molecule radiopharmaceutical candidate at a preclinical level engineered to focus on carbonic anhydrase IX (CA9). The CA9 is a transmembrane protein that is crucial in metastasis and cancer cell growth under hypoxic conditions. The preclinical studies have highlighted the proven efficacy, advising that the WT-7695 has the required capability to be a best-in-class, excellent radiopharmaceutical candidate.
Mansi Kadam is a market research writer with over 3 years of experience analyzing trends in the healthcare industry. At Towards Healthcare, she covers innovations in medical sector, sustainability initiatives, and the evolving regulatory landscape.
